Replies to post #277586 on Anavex Life Sciences Corp (AVXL)

[frrol]

Looking forward to seeing the results and that CDR-COA change. Exciting. Your clinical comparatives will be helpful.

[imho]

Many studies with negative and mediocre results are presented at meetings like tihis, often late-breaking.

Normally, I would counter with the fact that the 10/15 PR headlined "positive" results. Missling indicating "statistical significance" on most if not all measures.

The fear I have is that Missling has a poor track record of "describing" things. Missing deadlines and "tip of the iceberg" quotes do nothing for me, as far as having confidence in his statements.

Having said all that, if the data does back the PR, the bullish case for AVXL, as preached on this message board, may be more than warranted.

IMHO

[bas2020]

Many studies with negative and mediocre results are presented at meetings like this, often late-breaking.

You're overlooking one big detail... this was a PDD study (not AD) and was likely brought to the CTAD board after the LB deadline. A company doesn't rush negative or mediocre news to a CTAD conference as late-breaking. Get real!

[Steady_T]

That may be true. Missling had a choice about choosing to present at CTAD. I don't think he would choose to present mediocre news in such a forum.